Cue Biopharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Cue Biopharma, Inc. on November 17, 2025. The report discloses a material event regarding the departure of a senior executive officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial figure disclosed relates to executive severance compensation.
Material Changes
On November 17, 2025, the Company announced the termination of Matteo Levisetti, Chief Medical Officer, effective November 28, 2025. This departure triggers specific severance obligations under his employment agreement.
Management Commentary and Contingencies
Dr. Levisetti's severance package is contingent upon the execution and non-revocation of a separation and release of claims agreement. The package includes:
- Cash Severance: A lump sum payment of $556,837.60 (less applicable taxes), representing nine months of base salary plus a prorated portion of the 2025 target annual bonus.
- Health Benefits: Company payment of full COBRA premiums for up to nine months, or until the earlier of new comparable employment or COBRA termination.
The filing contains no forward-looking guidance, risk factors, or unusual items beyond the executive departure.
Investor Verification Checklist
- Confirm the execution of the separation and release of claims agreement to validate the $556,837.60 severance liability.
- Monitor for the appointment of a new Chief Medical Officer to assess potential impacts on clinical development timelines.
- Review subsequent filings for any changes to the Company's cash burn rate resulting from the severance payment.